Small Molecule Alternative

Develop small molecule alternatives for validated novel pathways and targets.

Low Risk Strategy as Pathways are Proven : We chose pathways and targets that are pathognomic to the disease in focus, with validated evidence in the literature. These pathways are already validated for safety concerns and liabilities, with advanced evidence efficacy for the indication. We design a new molecule entity from the existing library of de novo molecules using GenAI. It helps us bring novel therapies to emerging markets earlier as well as provide access to broader population globally.

Less Complicated Development and Manufacturing : We focus on small molecular alternatives where development is easier and incurs comparatively lesser costs. We use existing manufacturing capabilities in emerging markets like India, where very high-quality manufacturing machinery and processes are established, to develop products to serve global needs.

Comparatively Shorter Development Cycle : Considering lower safety concerns and shorter monitoring requirements, small molecules can be brought comparatively faster to the market.

Oral Alternatives Requiring Lesser Monitoring : Oral therapies are administered in outpatient settings without the need for hospitalization and with the requirement of being set up closer to home for monitoring adverse events. This helps serve a broader population base, including remote areas without health care infrastructure, which is still a need in low-income countries.